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Abstract 
Purpose: To investigate the effects of Plantago depressa Willd. extract (PDWE) on hyperuricemia in 
rats.  
Methods: The effect of PDWE was investigated in hyperuricemic rats induced by potassium oxonate. 
PDWE were fed to hyperuricemic rats daily at a dose of 160, 320 and 640 mg/kg for 10 days; allopurinol 
(5 mg/kg) was given as positive control. Serum and urine levels of uric acid and creatinine were 
determined by colorimetric method.  
Results: PDWE inhibited xanthine oxidase (XOD) activity in serum (16.36 ± 1.16 U/L, p < 0.05) and 
liver (72.15 ± 5.26 U/g protein, p < 0.05), and also decreased levels of serum uric acid (2.43 ± 0.59 
mg/L, p < 0.05), serum creatinine (0.42 ± 0.15 µmol/L) and blood urea nitrogen (BUN, 9.58 ± 0.72 
mmol/L, p < 0.05), but increased levels of urine uric acid (39.23 ± 8.22 mg/L, p < 0.05) and urine 
creatinine (32.24 ± 1.69 mmol/L, p < 0.05) in the renal tissue of hyperuricemic rats.  
Conclusion: PDWE exerts uricosuric action by regulating renal urate transporters to ameliorate renal 
dysfunction in hyperuricemic rats. 
 
Keywords: Plantago depressa Willd., Hyperuricemic, Renal urate transporters, Renal dysfunction, 
Uricosuric action 
  
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Hyperuricemia is characterized by abnormally 
high levels of uric acid in the blood. In general, 
the upper end of the normal range is 360 µmol/L 
(6 mg/dL) for women and 416 µmol/L (7.0 mg/dL) 
for men.1 Hyperuricemia has also emerged as a 
metabolic disease which threatens human 
health, and is considered as an important risk 
factor for gout and may be associated with 
metabolic syndromes, stroke incidence, chronic 
kidney disease and cardiovascular disease [1,2]. 
Current anti-hyperuricemic agents in use include: 
xanthine oxidase (XOD) inhibitors, which inhibit 
the activity of XOD, an enzyme involved in purine 
metabolism, of which allopurinol is the most often 
prescribed; uricosuric agents, which act on the 
proximal tubules in the kidneys to interfere with 
the absorption of uric acid from the urine back 
into the blood, and include probenecid, 
benzbromarone and sulfinpyrazone; and the 
enzyme urate oxidase, including the recombinant 
form rasburicase, which catalyzes the oxidation 
of uric acid to the more soluble allantoin which is 
more readily excreted via the kidneys [3-5]. 
However, these existing anti-hyperuricemic 
agents possess undesirable effects. For 
example, allopurinol, which is the drug of choice, 
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has side effects including gastrointestinal 
irritation, bone marrow suppression, 
hypersensitivity syndromes, hepatitis and 
worsening renal function, which are unable to be 
tolerated by approximately 5 % of patients [6]. 
Uricosuric agents are used in patients with 
allopurinol-allergic syndromes as well as in under 
excreters with normal renal function and no 
history of urolithiasis. However, uricosuric 
agents, such as benzbromarone, also have 
issues. Though benzbromarone is still marketed 
in several countries by other drug companies, it 
was withdrawn by Sanofi-Synthélabo in 2003 
after reports of serious hepatotoxicity. Similarly, 
the uricosuric agents probenecid and 
sulfinpyrazone have been reported to be 
nephrotoxic when used to treat hyperuricemia 
associated with moderate chronic renal 
insufficiency. Enzyme therapy using urate 
oxidase is only for treating severe hyperuricemia 
and is not widely used. Thus, anti-hyperuricemic 
agents have been limited in their clinical use due 
to their severe side effects. Therefore, it is 
important to search for alternative anti-
hyperuricemic agents with more favorable 
toxicological profiles, and in particular from 
natural sources [7]. 
 
Plantago depressa Willd. is widely used as a 
traditional Chinese herb for its efficiency in 
treating gouty diseases such as hyperuricemia, 
gout and inflammatory arthritis in China [8-9], but 
its actual mechanisms in the hypouricemic 
process remains unclear.  
 
This study is to investigate therapeutic effects of 
PDWE on XOD activity and urate excretion in 




Plant material and extraction 
 
Samples of Plantago depressa Willd. were 
collected from Guilin City, Guangxi Province in 
China in September 2015. Taxonomic 
authentication of the plant was performed by 
Professor Li He of Hubei University of Arts and 
Science in China. A voucher specimen (no. 
PDWE 20150922) was deposited in the 
Herbarium of College of Pharmacy, Hubei 
University of Arts and Science, China for future 
reference. 
 
The whole plant of Plantago depressa Willd. was 
dried in a drying oven at 100 oC for 12 h. An 
aqueous extract of DTM was obtained by 
steeping the dried Plantago depressa Willd. in 
water at 60 oC three times, each for 1 h in an 
oven and then freeze-drying the last extract thus 
obtained. One gram powder was obtained from 
about 2.0 g dried sample, i.e., a yield of 50.0 %. 
 
Animals and experimental procedures 
 
Male SD rats, weighing 180 - 220 g, were 
purchased from Animal Experimental Center, 
Wuhan University, China. The rat experiment 
was approved by the Animal Care and Use 
Committee of Hubei University of Arts and 
Science (approval ref no. 20111016) and was 
carried out in compliance with Directive 
2010/63/EU on the Handling of Animals used for 
Scientific Purposes [10]. 
 
Potassium oxonate was used to induce 
hyperuricemia in mice as previously reported 
[11,12]. Sixty rats were divided into six groups of 
ten rats each: normal group, model group, 
allopurinol group, high dose, middle dose and 
low dose of PDWE groups. Model rats were 
treated with 250 mg/kg oxonate. Allopurinol 
group rats were treated with allopurinol (5 
mg/kg); high dose, middle dose and low dose of 
of PDWE group rats were treated with 640 
mg/kg, 320 mg/kg and 160 mg/kg PDWE 
respectively. Normal group rats and negative 
control group rats were administered water. 
 
Except normal mice group, others were orally 
administered 250 mg/kg oxonate once daily for 7 
consecutive days to induce hyperuricemia. The 
drugs (allopurinol and PDWE) were dispersed in 
water and were orally administered once daily 




After 10 days of treatment, animals were 
sacrificed by cervical vertebra. Blood samples 
were collected and centrifuged at 3500 × g for 20 
min to obtain serum. The levels of XOD activities 
in serum and liver, serum and urinary levels of 
uric acid (UA), creatinine (Cr) and blood urea 
nitrogen (BUN) were determined by colorimetric 
methods using commercially available kits 
(purchased from Nanjing Jiancheng Biological 
Technology Co., Ltd., China) according to the 
manufacturers’ instructions. 
 
Data analysis  
 
All statistics were analyzed using Statistical 
Package SPSS 18.0 (SPSS Inc, Illinois, Chicago, 
USA) and are expressed as mean ± standard 
error of mean (SEM), and analyzed by one-way 
analysis of variance (ANOVA) followed by 
Dunnett’s t-test. P < 0.05 was considered 
statistically significant. 
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Effect of PDWE on serum and urinary levels 
of UA, Cr, and BUN  
 
The SUA level of model rats is significantly higher 
than those of normal rats   after orally 
administered with potassium oxonate (p < 0.05). 
Over a period of 10 days of treatment, the SUA 
level was suppressed significantly (p < 0.05) by 
PDWE treatment at the dose of 160 - 640 mg/kg, 
while the levels of UUA were increased 
significantly (p < 0.05) compared with model 
group (Table 1). High dose of PDWE also had 
significant effects on serum and hepatic XOD 
activities in hyperuricemic mice as showed in 
Table 2. Allopurinol at the dose of 5 mg/kg 
significantly suppressed hepatic XOD activity of 
hyperuricemic rats (p < 0.01). Compared with the 
normal group, the levels of BUN and SCr were 
suppressed significantly (both p < 0.05) by 
PDWE treatments at a dose of 160 - 640 mg/kg. 
Conversely, UCr levels at the treated doses was 
approximately 3 times more than that of 
allopurinol at a dose of 5 mg/kg and 
approximately 4 times more than that of the 
model group. Although both SUA and UUA levels 
in PDWE-treated rats were higher than those in 
allopurinol-treated mice, PDWE dose-




Uric acid is the 
metabolism and is excreted in urine in humans, 
who have lost hepatic uricase activity during 
evolution. As a consequence, humans have 
higher serum uric acid levels compared with 
most mammals. Several factors including high-
protein diet, alcohol consumption, high cell 
turnover, and renal failure, can result in elevated 
uric acid levels. In recent decades, 
hyperuricemia has received increasing attention 
as a major public health problem because of its 
high prevalence and the associated increases in 
the risk of hypertension, cardiovascular disease, 
diabetes and chronic kidney disease [11,12]. 
 
Some studies also demonstrated that traditional 
Chinese medicine could down-regulate hepatic 
XOD and enhance renal urate excretion in 
hyperuricemic mice [13]. However, in our clinical 
practice and previous reports, inhibitory effect of 
traditional Chinese medicine simiao pill on XOD 
was lower than that of allopurinol. Therefore, to 
reverse the complicated pathologic state of 
hyperuricemia in the early phase, PDWE was 
used to enhance renal urate excretion. 
Compared with model group, the levels of SUA 
were suppressed significantly by PDWE 
treatment at the dose of 160 - 640 mg/kg, while 
the levels of UUA were increased significantly.  
 
High dose of PDWE also had significant effects 
on serum and hepatic XOD activities in 
hyperuricemic mice. Increasing clinical reports 
have shown that hyperuricemia associated with 
an increasing risk of not only gout, but also 
chronic nephritis and 
 
Table 1: Effect of PDWE on serum and urinary levels of UA, Cr and BUN (n = 10) 
 











Normal - 1.26±0.14* 37.23±5.59* 0.23±0.11* 45.26±3.27* 8.59±0.78* 
Negative 
control - 6.34±0.72 13.28±4.36 0.84±0.27 18.34±4.38 17.44±1.18 
Allopurinol 5 1.94±0.32* 18.64±5.13 0.35±0.16* 25.14±3.25* 9.84±1.16* 
PDWE-L 160 3.75±1.25* 20.14±6.15 0.61±0.17* 17.38±2.27 14.25±0.62* 
PDWE-M 320 2.64±0.85* 28.25±7.13* 0.54±0.25* 24.52±2.87* 12.34±0.68* 
PDWE-H 640 2.43±0.59* 39.23±8.22* 0.42±0.15* 32.24±1.69* 9.58±0.72* 
Data are expressed as mean ± SEM; p < 0.05 compared with model group. Key: PDWE-L = low 
dose of PDWE; PDWE-M = middle dose of PDWE; PDWE-H = high dose of PDWE 
 
   Table 2: Effect of PDWE on XOD activity in serum and liver of hyperuricemic mice (n = 10) 
 
Group Dose (mg/kg) 
Serum XOD  
(U/L) 
Liver XOD  
(U/g protein) 
Normal - 15.28±1.25* 59.46±3.38* 
Model - 29.26±1.38 82.16±4.26 
Allopurinol 5 18.24±1.23* 35.33±4.19* 
PDWE-L 160 25.21±1.25 76.46±5.25 
PDWE-M 320 23.24±1.17 74.18±5.34 
PDWE-H 640 16.36±1.16* 72.15±5.26* 
Data is expressed as mean ± SEM; p < 0.05 compared with model group. Key: PDWE-L = 
low dose of PDWE; PDWE-M = middle dose of PDWE; PDWE-H = high dose of PDWE 
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renal dysfunction [14]. BUN and SCr levels are 
useful indicators of renal function. Renal damage 
could be accompanied by an increase in BUN 
and SCr indicating reduced urea and creatinine 
clearance [15]. Compared with the normal group, 
the levels of BUN and SCr were suppressed 
significantly by PDWE treatments at a dose of 
160 - 640 mg/kg, and conversely, the degree of 
promotion of UCr levels induced by PDWE at the 
treated doses was approximately 3 times more 




The findings of this study reveal that PDWE 
successfully treated hyperuricemic in rats by 
regulating renal urate transporters. Thus, the 
plant has the potential to be developed for 
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